Natriuretic peptide testing strategies in heart failure: A 2023 update
Issued Date
2023-01-01
Resource Type
ISSN
00652423
eISSN
21629471
Scopus ID
2-s2.0-85177879777
Journal Title
Advances in Clinical Chemistry
Rights Holder(s)
SCOPUS
Bibliographic Citation
Advances in Clinical Chemistry (2023)
Suggested Citation
Chaikijurajai T., Rincon-Choles H., Tang W.H.W. Natriuretic peptide testing strategies in heart failure: A 2023 update. Advances in Clinical Chemistry (2023). doi:10.1016/bs.acc.2023.11.005 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/91298
Title
Natriuretic peptide testing strategies in heart failure: A 2023 update
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Natriuretic peptides (NPs), including B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), have been recommended as standard biomarkers for diagnosing heart failure (HF), and one of the strongest risk predictors for mortality and HF hospitalization regardless of ejection fraction (EF) and etiology of HF. BNP is an active neurohormone opposing renin-angiotensin-aldosterone and sympathetic nervous system overactivated in HF, whereas NT-proBNP is an inactive prohormone released from cardiomyocytes in response to wall stress. Despite substantial advances in the development of guideline-directed medical therapy (GDMT) for HF with reduced EF, studies demonstrating direct benefits of NP-guided chronic HF therapy on mortality, HF hospitalization, and GDMT optimization have yielded conflicting results. However, accumulating evidence shows that achieving prespecified BNP or NT-proBNP target over time is significantly associated with favorable outcomes, suggesting that benefits of serially measured NPs may be limited to particular groups of HF patients, such as those with extreme levels of baseline BNP or NT-proBNP, which could represent severe phenotypes of HF associated with natriuretic peptide resistance or cardiorenal syndrome. Over the past decade, clinical utilization of BNP and NT-proBNP has been expanded, especially using serial NP measurements for guiding HF therapy, optimizing GDMT and identifying at-risk patients with HF phenotypes who may be minimally symptomatic or asymptomatic.